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Ssigniﬁcantly different in the 3 groups (Figure). Compared with pts in whom MC
caused no change in RF, there was a trend toward improved survival out to 2 years in
pts with acutely improved RF and signiﬁcantly poorer survival in pts with worsened
RF. Multivariate Cox regression analysis revealed DKDOQI – next to MC failure,
presence of dilated cardiomyopathy, and peripheral arterial disease – as independently
predictive of mortality (hazard ratios vs. pts with worsened RF: improved RF 0.31
[p¼0.0005], unchanged RF 0.46 [p¼0.006]). DKDOQI did not impact the rate of
rehospitalization for HF.
Conclusions: MC in surgical high-risk pts acutely improves RF in about one quarter
of pts. These pts exhibit improved survival compared to those without acute change





Freedom from death at 1 year 74%
Freedom from MR >2+ at 1 year in surviving patients 84%
Freedom from mitral valve surgery at 1 year 97%
Improvement in LVEDV at 1 year -15  28 ml
% patients with NYHA Class III/IV: Baseline/ 1 year 87%/ 19%
Improvement in SF-36 QoL Physical Component
Summary at 1 year
4.1  9.3 points
Improvement in SF-36 QoL Mental Component Summary
at 1 year
3.4  11.6 points
Rate of hospitalizations for HF
(1-year pre-procedure/ 1-year post-procedure)
0.80/ 0.41TCT-92
Transcatheter Mitral Valve-in-Valve / Valve-in-Ring Implantations for
Degenerative Post Surgical Valves: Results from the Global Valve-in-Valve
Registry
Danny Dvir1, Ran Kornowski2, Dominique Himbert3, Francesco Maisano4,
Ulrich Schaefer5, Hendrik Treede6, Sabine Bleiziffer7, Manuel Wilbring8,
Enrico Ferrari9, Didier Tchetche10, Claudia Fiorina11, Anna Sonia Petronio12,
Anson Cheung13, Mathew Williams14, Webb John15
1St Paul's Hospital, Vancouver, British Columbia, 2Rabin Medical Center, Petach
Tikva, Israel, 3Bichat, Paris, a, 4San Raffaele Hospital, Milan, Italy, 5St Georg
Hospital, Hamburg, 011, 6Hamburg University, Hamburg, Germany, 7German Heart
Center Munich, Munich, Germany, 8University Heart Center Dresden, Dresden,
Germany, Dresden, a, 9University Hospital of Lausanne, Lausanne, Switzerland,
10Clinique Pasteur, Toulouse, France, 11Cardia Catheterization Laboratory, Brescia,
Italy, 12University of Pisa, Pisa, Italy, 13St Pauls Hospital, Vancouver, British
Columbia, 14Presbyterian Hospital/Columbia University, New York, NY, 15St Pauls
Hospital, vancouver, british Columbia
Background: Transcatheter mitral valve-in-valve / valve-in-ring implantation is an
emerging therapeutic alternative for patients with failed mitral valves after surgical
intervention and may obviate the need for a redo operation. We aimed to evaluate the
clinical results of this technique using a large worldwide registry.
Methods: The registry included 134 patients with degenerated mitral valves after
surgical intervention (12.7% ring only, median of 9 years post procedure) from 22
centers. Mean age 74.3  11 years; 64.4% female (STS score 16.1  13.1%). The
mode of failure was regurgitation (n¼64, 47.8%), stenosis (n¼34, 25.4%), and
combined stenosis and regurgitation (n¼36, 26.9%).
Results: Transcatheter Edwards SAPIEN (Edwards Lifesciences, Irvine, CA)
implantation was performed in all cases (23 mm in 15.7%, 26 mm in 58.2%, and 29
mm in 26.1%). Procedural access was transapical in 117 cases (87.3%); transseptal in
12 (9%), and through the left atrium via right mini-thoracotomy in 5 (3.7%). Twenty
combined procedures (14.9%) included aortic valve-in-valves, aortic valve replace-
ment, tricuspid valve-in-ring implantation, and paravalvular leak closure. Device
malposition appeared in 6 cases (4.5% of cases) and post implantation valvuloplasty
was utilized in 8%. Post-procedure, mitral valve area was 2  0.6 cm2, valve
maximum / mean gradients were 13  6.3 mmHg / 6.4  3, respectively, and
signiﬁcant mitral regurgitation (+2) was observed in 5.2% of patients. Median length
of hospital stay was 7 days. At 30-day follow-up, all-cause mortality was 8.2%, 1.5%
of patients had stroke and 79.2% were at New York Heart Association functional
class I/II.
Conclusions: Mitral valve-in-valve/ valve-in-ring implantations, performed in
extremely high-risk patients, were clinically effective in most patients with degener-
ative mitral valves after surgery. The safety and efﬁcacy of this approach will be
further examined.B30 JACC Vol 62/18/Suppl B j October 27–November 1, 2013TCT-93
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Background: Elderly patients with severe mitral regurgitation (MR) often present
with multiple serious co-morbidities including heart failure (HF), and therefore are
not considered candidates for mitral valve surgery due to high risk of surgical
mortality and morbidity. These patients have limited options as no medical therapy
is directed speciﬁcally at reducing MR. The MitraClip system has emerged
as an important non-surgical treatment option. Results in the high risk octoge-
narian cohort treated with MitraClip in the EVEREST II studies have not been
presented.
Methods: High risk patients age 80 years had 3+/4+ MR at baseline and were
deemed high risk for surgery as predicted by STS mortality risk score of 12%, or
surgeon assessment based on pre-speciﬁed factors. Echocardiograms were evaluated
by an independent core lab. Clinical outcomes at 1 year including change in left
ventricular (LV) volume, NYHA class, quality of life (QoL), and hospitalizations for
HF were analyzed.
Results: A total of 146 high risk octogenarians (mean age 85 yrs) underwent the
MitraClip procedure. Baseline co-morbidities included CAD (80%), prior CABG
(47%) and moderate to severe renal disease (33%). Baseline LVEF was 5214%.
Predicted mortality (STS risk score) was 158%. Actual 30-day mortality was 7.5%.
Despite advanced age and burden of co-morbidities, 84% of octogenarians achieved
MR reduction to 2+ post-MitraClip and 90% were discharged home. At 1 year,
octogenarians showed improvements from baseline in clinical and functional measures
(Table 1).Conclusions: In high risk octogenarians, the MitraClip procedure resulted in mean-
ingful improvements in MR severity, LV volumes and QoL. Percutaneous reduction
of MR with the MitraClip is a therapeutic option for high risk elderly patients with
multiple co-morbidities who are not candidates for surgery.j TCT Abstracts/ORAL/Percutaneous Treatment of Mitral Valve Disease
